VcMMAE

    • 货号:MC0559
      • CasNo:
      • 646502-53-6
      • 分子式:
      • C68H105N11O15
      • 纯度:
      • 99.11%
      • 靶点:
      • Drug-Linker Conjugates for ADC
      • IC50:
      • No data
      • 体外研究:
      • Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].
      • 体内研究:
      • Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models[2].
      • 简介:
      • VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
      • 特异性:
      • Target: Drug-Linker Conjugates for ADC. Fields: VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via th
      • 浓度:
      • 99.11%
      • 储存:
      • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
      • 其他名称:
      • VC-MMAE,Vc MMAE
      • 分子量:
      • 1316.63
      • 产品图片